CEACAM5 and ovarian carcinoma: First results of a MV-CEA dose-escalating clinical trial on refractory ovarian cancer (NCT00408590) were published in 2010.14 Patients were treated with MV-CEA through an intraperitoneal (i.p.)catheter every 4 weeks for up to six courses (application scheme depicted in Figure 1a).